Home > Riviste > Minerva Gastroenterologica e Dietologica > Fascicoli precedenti > Articles online first > Minerva Gastroenterologica e Dietologica 2015 Oct 08



Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca


Per citare questo articolo



Minerva Gastroenterologica e Dietologica 2015 Oct 08


lingua: Inglese

Supplementary management of functional, hepatic damage with Liverubin (pharma-standard Silymarin). A 3-month registry

Pellegrini L., Belcaro G., Dugall M., Hu S., Gizzi G., Corsi M., Hosoi M., Luzzi R., Feragalli B., Cotellese R.

Irvine3 labs & PAP/PEA Screening Project and the International Irvine Network, Spoltore and San Valentino, Dept Sc Med Or Biotec, G D’Annunzio University, Ch-Pe, Italy


Mild, temporary hepatic failure (MTHF) is a common clinical problem; in case of repeated episodes MTHF may cause chronic liver impairment. This registry has evaluated MTHF in subjects using Liverubin (standardized Silymarin) for 8 weeks.
METHODS: MTHF was evaluated in a registry study. In all subjects viral hepatitis markers were negative at inclusion. Different possible causes of MTHF had been considered. In these subjects alcohol was not a main factor. The registry included MTHF patients with decreased albumin levels, increased total bilirubin, altered hepatic function enzymes, increased oxidative stress. Two management groups were created: a standard management (SM) group and a SM+Liverubin group; 32 Liverubin patients and 33 SM subjects completed the registry. Liverubin was used at the dosage of two tablets (each equivalent to 140 mg) daily.
RESULTS: Distribution of symptoms, blood test values and ultrasound results were comparable. Symptoms observed at inclusion disappeared at 3 months in both groups. The increase in albumin levels was significantly (P<0.05 at 4 weeks) faster and the final blood tests improved more with Liverubin. Total bilirubin was reduced with the supplement (better than in controls; P<0.05). Direct bilirubin values improved more in the supplement group at 3 months (P<0.05). The decrease of SGPT and AST- ASAT was more evident in the supplement group (P<0.05). Alkaline phosphatase value was normalized at in Liverubin patients; values decreased less in controls (P<0.05). Gamma GT decreased more with Liverubin. ESR was decreased in both groups (significantly more with Liverubin: P<0.05). There was a less important decrease in controls at 3 months. The white cell count was also better with the supplement group; P<0.05). Plasma free radicals - significantly elevated in both groups at inclusion – decreased more with the supplement at 3 months. All other blood tests (including hematocrit, renal function tests) were within the normal range at inclusion and at 3 months in both groups. Hepatitis markers were negative at inclusion and at end-registry. Safety and tolerability were optimal (no side effect was registered).
CONCLUSION: In conclusion, data from this pilot, registry study indicate a significant activity of Liverubin associated with a very good safety profile, in patients with temporary hepatic failure. The recovery of hepatic function is faster and more effective with Liverubin compared to the best “standard” management.

inizio pagina